Simon Portsmouth

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

Frederick G. Hayden, Norio Sugaya, Nobuo Hirotsu et al. · New England Journal of Medicine · 2018 · 878 citations · Full text

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 732 citations

Antimicrobial Susceptibility, Health Sciences, Carbapenem-resistant Gram-negative Bacteria +11

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 387 citations

Urological Research, Urology, Gram-negative Uropathogens +10

Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial

Michael G. Ison, Simon Portsmouth, Yuki Yoshida et al. · The Lancet Infectious Diseases · 2020 · 251 citations

Baloxavir Marboxil, Pediatrics, Uncomplicated Influenza +5

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza

Takeki Uehara, Frederick G. Hayden, Keiko Kawaguchi et al. · The Journal of Infectious Diseases · 2019 · 189 citations · Full text